Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma

Inclusion Criteria: 1. Age 18\~65 years old, male or female 2. Signed informed consent 3. Diagnosis of hepatocellular carcinoma (HCC), surgery can not be performed but TACE treatment can be carried out. 4. The recurrence of HCC was found after the operation without distant metastasis. 5. The Eastern Cooperative Oncology Group (ECOG) score ≤2 6. Child-Pugh score of liver function ≤ 9 7. Routine blood meets the requirements. Exclusion Criteria: 1. Expected Overall survival \< 3 months 2. The tumor size or quantity is not suitable for interventional treatment or portal vein tumor thrombus 3. Liver function is Childs Pugh C 4. Had received TACE therapy previously or in radiotherapy at present,or taking Sola Feeney 5. Other serious diseases:the heart,lung, kidney, digestive, nervous, mental disorders, immune regulatory diseases, metabolic diseases, infectious diseases, etc. 6. Unable or unwilling to provide informed consent, or fail to comply with the test requirements.